Packaging systems provide strong Q3 sales growth for West

By Dan Stanton

- Last updated on GMT

Related tags Analyst david windley Pharmacology

West reports strong Q3 revenue
West reports strong Q3 revenue
West has reported a 12.5% growth in revenue year-over-year due to a strong quarter in Pharmaceutical Packaging Systems (PPS) sales.

For Q3 2013, West Pharmaceutical Services reported operating income up 51% on last year to $39.7m (€29.4m) on total sales of $341.8m (€253m). Whilst Pharmaceutical Delivery Systems (PDS) rose marginally, it was PPS that produced $251.5m worth of revenue for the quarter, up 16.5%.

“Management has executed its Packaging Systems strategy very well,”​ noted Jeffries’ analyst David Windley, “and the company continues to benefit from its dominant injectibles packaging market share and high barriers to entry.”

He continued to add sales have been continuing to creep up thanks to changes that include drug development shifts toward biologics, and transient inventory stocking, whilst the “record margin” ​was due to the mix of high-value products and a pricing drive.

The company also attributed high sales of its Westar and FluroTec products to the results, especially in markets outside the US with CEO Don Morel speaking of “strong Asia-Pacific demand”​ in a conference call discussing results.

In September​ the firm began construction on a second Chinese manufacturing facility in Shanghai, citing the growing injectables market in the region.

Crystal Zenith

German contract filler Vetter recently added a second filling line​ at a site in Chicago, US, to support a partnership with West going back to 2011​ for its Crystal Zenith (CZ) drug delivery system.

The prefillable syringe system - developed by Japanese firm Daikyo Seiko - is currently in clinical trials but the company and analysts alike are awaiting for a sales boom once approved.

“Management continues to expect a late 2015, early 2016 time frame for commercial volumes of CZ,”​ Windley said.

On top of significant revenue increase, this would also help West drive commercial manufacturing and reduce the capital expenditure intensity of the firm’s production capacity, he added.

Related news

Show more

Related products

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 04-May-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Content provided by Lonza Small Molecules | 28-Mar-2023 | White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Related suppliers

Follow us


View more